Live tape
Top 8, mentions 7d15,833MSFT3,115 mentions▲ +0.09GOOGL2,192 mentions▲ +0.05AAPL2,144 mentions▲ +0.07META2,096 mentions▲ +0.04SNDK1,861 mentions▲ +0.06NVDA1,608 mentions▲ +0.07SPCX1,575 mentions▲ +0.06AMZN1,242 mentions▲ +0.08

Equity · Healthcare

ACAD

ACADIA Pharmaceuticals Inc. · NasdaqGS

$26.02 +2.50% 1D Finazon · prior-day close · Jul 28, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of ACAD over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 63 sessions over that window: $22.18 on 4 May 2026 through $26.02 on 28 July 2026. Finazon · prior-day close.

Market cap $4.5B
P/E (TTM) 36.7
52-week range $20.00 – $28.00
Avg volume 342.7K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

ACAD insider trades

SEC Form 4 · last 90 days · newest reported trade 26 Jun 2026
Open-market buys 0
Open-market sells 4
Net sold $518K
Non-trade filings 6
Date Insider Type Shares Value
26 Jun 2026 Kihara James PRINCIPAL ACCOUNTING OFFICER Sell 11,421 $298K
26 May 2026 Kihara James PRINCIPAL ACCOUNTING OFFICER Sell 5,401 $114K
04 May 2026 Kihara James PRINCIPAL ACCOUNTING OFFICER Sell 1,332 $29K
04 May 2026 Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Sell 3,506 $76K
Compensation mechanics (6 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
29 May 2026 HARRIGAN EDMUND Director Option exercise 8,107
29 May 2026 Brege Laura Director Option exercise 8,107
29 May 2026 Daly James M Director Option exercise 8,107
29 May 2026 Poole Jonathan Director Option exercise 2,010
29 May 2026 GAROFALO ELIZABETH A. Director Option exercise 8,107
29 May 2026 Ndu Adora Director Option exercise 8,107

ACAD reported financials

SEC EDGAR XBRL

ACAD reported revenue of $1.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $391.0M.

Figure Reported Period
Revenue $1.1B 31 Dec 2025 fiscal year
Net income $391.0M 31 Dec 2025 fiscal year
Diluted EPS $2.30 31 Dec 2025 fiscal year
Total assets $1.6B 31 Mar 2026 at period end
Total equity $1.2B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

ACAD earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $0.02 —
31 Dec 2025 FY 2025 $2.30 —
30 Sep 2025 Q3 2025 $0.42 —
30 Jun 2025 Q2 2025 $0.16 —

Reported figures & scheduled dates · SEC EDGAR filings

ACAD institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a ACAD position for the quarter ended 31 Mar 2026 — a combined $1.2B; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 42,896,690 $954.9M
Point72 Asset Management Held (±25%) −23.7% shares 2,577,916 $57.4M
Renaissance Technologies Held (±25%) +12.5% shares 1,724,196 $38.4M
Two Sigma Investments Trimmed −30.7% shares 775,121 $17.3M
Fisher Asset Management Held (±25%) +10.2% shares 732,872 $16.3M
D. E. Shaw & Co. Trimmed −28.9% shares 729,836 $16.2M
Millennium Management Added +27.4% shares 705,461 $15.7M
Citadel Advisors Trimmed −54.5% shares 622,760 $13.9M
AQR Capital Management Held (±25%) −12.7% shares 527,913 $11.8M
Balyasny Asset Management New position 312,982 $7.0M

Source: SEC EDGAR 13F filings

ACAD fails-to-deliver

SEC CNS data

On 30 Jun 2026, 251 shares of ACAD failed to deliver (about $6K) — the latest of 3 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 251 $6K <0.001%
29 Jun 2026 18,906 $479K 0.011%
26 Jun 2026 381 $9K <0.001%

Source: SEC fails-to-deliver (CNS) data